CLAIMS:

1. Use of PEGylated uricase ~~uric acid levels~~in the manufacture of a medicament for preventing an infusion reaction~~s~~ during PEGylated uricase therapy in a patient, ~~comprising the steps of:~~

~~a) obtaining a biological sample from said patient at least 2 hours after administration of a PEGylated uricase; and~~

~~b) determining uric acid levels in said biological sample, wherein a uric acid level of more than 4mg/dl indicating that PEGylated uricase therapy is to be discontinued to prevent infusion reactions~~wherein the preventing comprises regular monitoring of uric acid levels in the patient by determining uric acid levels in a biological sample from the patient at least 2 hours after each administration of the medicament to the patient and wherein a uric acid level of more than 4 mg/dl indicates that the PEGylated uricase therapy is to be discontinued to prevent infusion reactions.

2. The use according to claim 1, wherein ~~said uric acid level~~ the PEGylated uricase therapy is to be discontinued to prevent infusion reactions when said uric acid level is more than 5 mg/dl.

3. The use according to claim 1, wherein ~~said uric acid level~~the PEGylated uricase therapy is to be discontinued to prevent infusion reactions when said uric acid level is more than 6 mg/dl.

4. The use according to claim 1, wherein ~~said uric acid level~~the PEGylated uricase therapy is to be discontinued to prevent infusion reactions when said uric acid level is more than 7 mg/dl.

5. The use according to claim 1, wherein the medicament is formulated for administration ~~of PEGylated uricase is~~ at a dosage of 8mg every 2 weeks.

6. The use according to claim 1, wherein the medicament is formulated for administration ~~of PEGylated uricase is~~ at a dosage of 8 mg every 3 weeks.

7. The use according to claim 1, wherein the medicament is formulated for administration ~~of PEGylated uricase is~~ at a dosage of 8 mg every 4 weeks.

8. The use according to claim 1, wherein the medicament is formulated for administration ~~of PEGylated uricase is~~ at a dosage of 4mg every 2 weeks.

9. The use according to claim 1, wherein the medicament is formulated for administration ~~of PEGylated uricase is~~ at a dosage of 12 mg every 4 weeks.

10. The use according to claim 1, wherein said biological sample is selected from the group consisting of blood, serum and plasma.

11. The use according to claim 1, wherein the preventing comprises determining ~~said~~ uric acid levels in ~~said~~the biological sample from the patient ~~are determined~~ at least 6 hours after ~~the~~ administration of ~~PEGylated uricase~~the medicament.

12. The use according to claim 1, wherein the preventing comprises determining ~~said~~ uric acid levels in ~~said~~the biological sample from the patient ~~are determined~~ at least 24 hours after ~~the~~ administration of ~~PEGylated uricase~~the medicament.

13. The use according to claim 1, wherein ~~said~~the preventing comprises determining uric acid levels in ~~said~~the biological sample from the patient ~~are determined~~ 2 weeks after ~~the~~ administration of ~~PEGylated uricase~~the medicament.

14. The use according to claim 1, wherein ~~said~~the preventing comprises determining uric acid levels in ~~said~~the biological sample from the patient ~~are determined~~ 4 weeks after ~~the~~ administration of ~~PEGylated uricase~~the medicament.

15. The use according to claim 1, wherein said patient is suffering from gout.

16. The use according to claim 15, wherein said gout is refractory.

17. The use according to claim 15, wherein said gout is chronic or tophaceous.

18. The use according to claim 1 wherein the ~~administration of PEGylated uricase~~medicament is formulated for intraveneous administration.

19. Use of ~~uric acid levels to~~PEGylated uricase in the manufacture of a composition for predicting whether a patient treated with PEGylated uricase will develop infusion reaction ~~after being treated with PEGylated uricase comprising the steps of:~~

~~a) obtaining a biological sample from said patient at least 2 hours after administration of PEGylated uricase; and~~

~~b) determining uric acid levels in said biological sample,~~

wherein the predicting comprises regular monitoring of uric acid levels in the patient by determining ~~when said~~ uric acid levels in a biological sample from the patient at least 2 hours after each administration of the composition to the patient and wherein: (a) ~~is~~a uric acid level maintained at less than 4mg/dl indicat~~es~~~~ing~~ ~~said uric acid level is associated with~~ a lower likelihood of infusion reaction; ~~or when said~~and (b) a uric acid level ~~is measured~~ of at least 4 mg/dl ~~said determined uric acid level~~ indicat~~es~~~~ing~~ a higher likelihood of infusion reaction at a time point.

20. The use according to claim 19 wherein ~~said~~the uric acid level is associated with a lower likelihood of infusion reaction when said level is maintained at less than 5 mg/dl or ~~indicating that said determined~~the uric acid level is associated with a higher likelihood of infusion reaction at a time point when said level is measured at least 5 mg/dl.

21. The use according to claim 19 wherein ~~said~~the uric acid level is associated with a lower likelihood of infusion reaction when said level is maintained at less than 6 mg/dl or ~~indicating that said determined~~the uric acid level is associated with a higher likelihood of infusion reaction at a time point when said level is measured at least 6 mg/dl.

22. The use according to claim 19 wherein ~~said~~the uric acid level is associated with a lower likelihood of infusion reaction when said level is maintained at less than 7 mg/dl or ~~indicating that said determined~~the uric acid level is associated with a higher likelihood of infusion reaction at a time point when said level is measured at least 7 mg/dl.

23. The use according to claim 19, wherein ~~said~~the predicting comprises determining uric acid levels in ~~said~~the biological sample from the patient ~~are determined~~ at least 6 hours after ~~the~~ administration of ~~PEGylated uricase~~the composition.

24. The use according to claim 19, wherein ~~said~~the predicting comprises determining uric acid levels in ~~said~~the biological sample from the patient ~~are determined~~ at least 24 hours after ~~the~~ administration of ~~PEGylated uricase~~the composition.

25. The use according to claim 19, wherein ~~said~~the predicting comprises determining uric acid levels in ~~said~~the biological sample from the patient ~~are determined~~ 2 weeks after ~~the~~ administration of ~~PEGylated uricase~~the composition.

26. The use according to claim 19, wherein ~~said~~the predicting comprises determining uric acid levels in ~~said~~the biological sample from the patient ~~are determined~~ 4 weeks after ~~the~~ administration of ~~PEGylated uricase~~the composition.

27. Use of PEGylated uricase in the manufacture of a composition for~~uric acid levels to~~ predicting whether a patient treated with PEGylated uricase will develop antibody-mediated PEGylated uricase clearance ~~after being treated with PEGylated uricase~~ without measuring anti-PEGylated uricase and anti-PEG antibodies titer, ~~comprising the steps of:~~

~~a) obtaining a biological sample from said patient at least 2 hours after administration of PEGylated uricase; and~~

~~b) determining uric acid levels in said biological sample,~~

wherein the predicting comprises regular monitoring of uric acid levels in the patient by determining uric acid levels in a biological sample from the patient at least 2 hours after each administration of the composition to the patient and wherein: (a) ~~when said~~a uric acid level ~~is~~ maintained at less than 4 mg/dl indicates~~ing that uric acid level is associated with~~ a lower likelihood of antibody-mediated PEGylated uricase clearance; and (b) ~~or when said~~a uric acid level ~~is measured~~of at least 4 mg/dl indicates~~ing that said determined uric acid level is associated with~~ a higher likelihood of antibody-mediated PEGylated uricase clearance at a time point.

28. The use according to claim 27 wherein ~~said~~the uric acid level is associated with a lower likelihood of infusion reaction when said level is maintained at less than 5 mg/dl or ~~indicating that said determined~~the uric acid level is associated with a higher likelihood of infusion reaction at a time point when said level is measured at least 5 mg/dl.

29. The use according to claim 27 wherein ~~said~~the uric acid level is associated with a lower likelihood of infusion reaction when said level is maintained at less than 6 mg/dl or ~~indicating that said determined~~the uric acid level is associated with a higher likelihood of infusion reaction at a time point when said level is measured at least 6 mg/dl.

30. The use according to claim 27 wherein ~~said~~the uric acid level is associated with a lower likelihood of infusion reaction when said level is maintained at less than 7 mg/dl or ~~indicating that said determined~~the uric acid level is associated with a higher likelihood of infusion reaction at a time point when said level is measured at least 7 mg/dl.

31. The use according to claim 27, wherein ~~said~~the predicting comprises determining uric acid levels in ~~said~~the biological sample from the patient ~~are determined~~ at least 6 hours after ~~the~~ administration of ~~PEGylated uricase~~the composition.

32. The use according to claim 27, wherein ~~said~~the predicting comprises determining uric acid levels in ~~said~~the biological sample from the patient ~~are determined~~ at least 24 hours after ~~the~~ administration of ~~PEGylated uricase~~the composition.

33. The use according to claim 27, wherein ~~said~~the predicting comprises determining uric acid levels in ~~said~~the biological sample from the patient~~are determined~~ 2 weeks after ~~the~~ administration of ~~PEGylated uricase~~the composition.

34. The use according to claim 27, wherein ~~said~~the predicting comprises determining uric acid levels in ~~said~~the biological sample from the patient ~~are determined~~ 4 weeks after ~~the~~ administration of ~~PEGylated uricase~~the composition.

35. The use according to claim 1, wherein the medicament is formulated for administration at least every 2, 3, or 4 weeks.